Feed ESPR
ES

Esperion Therapeutics, Inc. ESPR · NASDAQ

$3.18 -0.16% (-$0.01)

Market cap
$661.1M
Enterprise value
$1.05B
P/E
-
Forward P/E
-
PEG
-
P/S
1.6x
P/FCF
-
EV/EBITDA
27.0x
ROIC
41.2%
Gross margin
31.4%
Net margin
-1.8%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
10.0x
Beta
1.06
Free float
100.0%

About the company

Esperion Therapeutics, Inc. is an American biopharmaceutical company based in Ann Arbor, Michigan, focused on developing and commercializing innovative therapies to lower cholesterol and prevent cardiovascular disease. The company primarily targets patients who are unable to achieve their cholesterol goals with commonly available statins, offering alternative treatment options aimed at improving quality of life and reducing the risk of cardiac events.

Sector

Healthcare

Industry

Biotechnology

CEO

Sheldon L. Koenig

Employees

294

Headquarters

Ann Arbor

Valuation

Is today's price reasonable?

  • What speaks for it: The share price is below the Bulios Fair Price.

Growth and estimates

Is it growing, and what comes next?

  • What speaks for it: Revenue grew by 75% a year over the last 3 years.
  • What to watch: It missed profit estimates 5 times in the last 8 quarters.

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

  • What speaks for it: It earns 41 USD a year on every 100 USD of invested capital.
  • What to watch: The company made a loss over the last 12 months.

Financial health

Can it carry its debt?

  • What to watch: Repaying its net debt would take 10.0 years of operating profit.
  • What to watch: It passes only 3 of the 9 points of the Piotroski financial health test.

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy